Androgen Deprivation Therapy (ADT) Market Restraints
According to American Cancer Society (ASC), several prostate cancers, which are treated with
ADT develop resistance to the treatment over a period of time (few months or years). Hormone
therapy is not useful in treating hormone refractory prostate cancer i.e. cancer, which is no
longer responding to hormone therapy. According to National Cancer Institute (NCI), National
Institutes of Health (NIH), along with prostate, androgens also contribute to functions of other
organs. Therefore, hormone deprivation therapy is associated with side effects such as hot
flashes, loss of bone density, erectile dysfunction, lowered libido, loss of muscular strength
mass, insulin resistance, and change in blood lipids, fatigue, mood swings, weight gain and
gynecomastia. These factors are expected to restrain the global androgen deprivation therapy
(ADT) market growth over the forecast period.
Request For Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/2559
Androgen Deprivation Therapy (ADT) Market Key Players
Some of the major players operating in the androgen deprivation therapy (ADT) market include,
Pfizer Inc., Astellas Pharma Inc., Johnson & Johnson, Novartis International AG, Veru Inc.,
Sanofi S.A., GlaxoSmithKline plc, Bayer AG, Orion Corporation, and AstraZeneca Plc.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-
ready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.